Skip to content

Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study

Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05762601
Acronym
COSMIC
Enrollment
12
Registered
2023-03-09
Start date
2023-02-15
Completion date
2025-09-30
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Complication, Myocardial Infarction, Myocardial Injury, Myocardial Ischemia

Keywords

Myocardial injury after noncardiac surgery, Perioperative myocardial infarction

Brief summary

The goal of this observational study is to collect health data on people who are at high risk of having heart complications and are having a surgery that is not on the heart. The main questions it aims to answer are: * Is this study feasible in terms of recruiting enough people to participate in this study? * How often do heart complications happen in people who are at high risk of heart complications and are having a surgery that is not on the heart? Participants will have their usual care and will also be asked to: * Have extra bloodwork done * Complete some surveys * Have two echocardiograms (ultrasounds of the heart) * Continue to follow-up with the research team for one year after their surgery Researchers will compare how often heart complications occur in this high risk population to a future study where participants will receive stem cells before their surgery.

Detailed description

This observational trial protocol is to collect baseline health data from participants undergoing intermediate to high-risk surgery and at high risk of developing perioperative myocardial ischemic complications for an upcoming Phase 1 trial that determines the feasibility of intravenous delivery of umbilical cord-derived (UC) mesenchymal stromal cells (MSCs) in the same patient population. Participants enrolled in this protocol, however, will not receive cell product; they will receive standard of care and serve as a lead in control group for the interventional study.

Interventions

None listed

Sponsors

Canadian Anesthesiologists' Society
CollaboratorOTHER
The Ottawa Hospital Academic Medical Association
CollaboratorOTHER
Ottawa Hospital Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

A participant must meet all 5 inclusion criteria to be eligible: * Referred for elective intermediate to high risk noncardiac surgery as defined by the American Heart Association guidelines (e.g., intrathoracic, open intraabdominal, or open vascular surgery) * 45 years of age or older * Revised cardiac risk index ≥ 2 * NT-proBNP level of ≥ 200 pg/mL * Able to provide informed consent

Exclusion criteria

* Experience an acute coronary syndrome, myocardial infarction, heart failure, or stroke within preceding 3 months * Coronary revascularization anticipated during the study period * Severe mitral/aortic valve stenosis * Evidence of clinically significant arrhythmia in last three months. * Major surgical procedure in previous 3 months * History of malignancy requiring surgery, chemotherapy, immunotherapy, or radiation within previous 5 years * Ongoing malignancy requiring surgical resection * Women who are pregnant, breastfeeding, or of childbearing potential who are unable to use a medically acceptable form of contraception throughout the study * Received any experimental cell therapy previously * Unable to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Participant Recruitment1 yearOur primary outcome is the feasibility of participant recruitment. This will be determined by measurements of recruitment efficiency: 1) proportion of potentially eligible participants that are successfully screened; 2) proportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded).
Baseline Frequency of adverse events and serious adverse events1 yearTo determine the baseline frequency of adverse events and serious adverse events in this high risk population

Secondary

MeasureTime frameDescription
Quality of life of participants1 yearThe EQ-5D-5L questionnaire will be used. This questionnaire measures quality of life using five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.

Countries

Canada

Contacts

Primary ContactMeredith Conboy, MSc
mconboy@ohri.ca613-737-8899
Backup ContactManoj M Lalu, MD, PhD
mlalu@toh.ca613-737-8899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026